Top

Published in:

01-12-2008

Imaging matrix metalloproteinases in cancer

Authors: Randy L. Scherer, J. Oliver McIntyre, Lynn M. Matrisian

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Abstract

Early detection of both primary tumors and metastatic disease remains a major challenge in the diagnosis and staging of cancer. The recognition of the role of MMPs in both the growth and metastasis of tumors has guided the development not only of therapeutic strategies utilizing synthetic, small-molecule MMP inhibitors (MMPIs), but has also catalyzed methods to detect and image tumors in vivo by means of tumor-associated proteolytic activity. These imaging approaches target MMPs involved in cancer progression via contrast agents linked to MMPIs or to MMP selective and specific substrates with sensitivity enhanced by amplification during enzymatic processing. This review draws attention to a variety of strategies utilized to image MMP activity in vivo.

Woessner, J. F., & Nagase, H. (2000). Matrix metalloproteinases and TIMPs. New York: Oxford University Press, Inc.CrossRef

Massova, I., Kotra, L. P., Fridman, R., & Mobashery, S. (1998). Matrix metalloproteinases: Structures, evolution, and diversification. FASEB Journal, 12(12), 1075–1095.PubMed

Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology, 17, 463–516.PubMedCrossRef

Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 3(69), 562–573.CrossRef

McKerrow, J. H., Bhargava, V., Hansell, E., Huling, S., Kuwahara, T., Matley, M., et al. (2000). A functional proteomics screen of proteases in colorectal carcinoma. Molecular Medicine, 5(6), 450–460.

Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000). Matrix metalloproteinases: Biologic activity and clinical implications. Journal of Clinical Oncology, 5(18), 1135–1149.

MacDougall, J. R., Bani, M. R., Lin, Y., Rak, J., & Kerbel, R. S. (1995). The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Research, 18(55), 4174–4181.

Vaisanen, A., Tuominen, H., Kallioinen, M., & Turpeenniemihujanen, T. (1996). Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. Journal of Pathology, 3(180), 283–289.CrossRef

Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., et al. (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research, 53, 5365–5369.PubMed

10.

Sternlicht, M. D., & Bergers, G. (2000). Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects. Emerging Therapeutic Targets, 4, 609–633.CrossRef

11.

Martin, M. D., & Matrisian, L. M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer and Metastasis Reviews, 26(3–4), 717–724.PubMedCrossRef

12.

Martin, M. D., & Matrisian, L. M. (2005). Matrix metalloproteinases as prognostic factors for cancer. Clinical Laboratory Investigations, 6(28), 16–18.

13.

Van de Wiele, C., & Oltenfreiter, R. (2006). Imaging probes targeting matrix metalloproteinases. Cancer Biotherapy & Radiopharmaceuticals, 5(21), 409–417.CrossRef

14.

Weissleder, R., & Ntziachristos, V. (2003). Shedding light onto live molecular targets. Nature Medicine, 1(9), 123–128.CrossRef

15.

McIntyre, J. O., Fingleton, B., Wells, K. S., Piston, D. W., Lynch, C. C., Gautam, S., et al. (2004). Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochemical Journal, Pt 3(377), 617–628.

16.

McIntyre, J. O., & Matrisian, L. M. (2003). Molecular imaging of proteolytic activity in cancer. Journal of Cellular Biochemistry, 6(90), 1087–1097.CrossRef

17.

Tsien, R. Y. (2005). Building and breeding molecules to spy on cells and tumors. FEBS Letters, 4(579), 927–932.CrossRef

18.

Weissleder, R., Tung, C. H., Mahmood, U., & Bogdanov Jr., A. (1999). In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology, 4(17), 375–378.CrossRef

19.

Bremer, C., Tung, C. H., & Weissleder, R. (2001). In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Medicine, 6(7), 743–748.CrossRef

20.

Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C. D., Forsyth, P., Edwards, D., et al. (1999). Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Annals of the New York Academy of Sciences, 878, 236–270.PubMedCrossRef

21.

Scherer, R., VanSaun, M., McIntyre, J. O., & Matrisian, L. M. (2008). Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Molecular Imaging, (in press).

22.

Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., & Tsien, R. Y. (2004). Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proceedings of the National Academy of Sciences of the United States of America, 51(101), 17867–17872.CrossRef

23.

Zheng, G., Chen, J., Stefflova, K., Jarvi, M., Li, H., & Wilson, B. C. (2007). Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proceedings of the National Academy of Sciences of the United States of America, 21(104), 8989–8994.CrossRef

24.

Levin, C. S. (2005). Primer on molecular imaging technology. European Journal of Nuclear Medicine and Molecular Imaging, 32(Suppl 2), S325–S345.PubMedCrossRef

25.

Wigdal, B. B. S., O’Brien, M., Lewis, K., Fan, F., & Wood, K. (2007). A novel bioluminescent platform for p’-requiring proteolytic activity studies. Proceedings of the 5th General Meeting of the International Proteolysis Society, Patras, Greece, p. 108

26.

Kubota, K. (2001). From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Annals of Nuclear Medicine, 6(15), 471–486.

27.

Brown, P. D. (1999). Clinical studies with matrix metalloproteinase inhibitors. APMIS, 1(107), 174–180.

28.

Zheng, Q. H., Fei, X., Liu, X., Wang, J. Q., Bin, S. H., Mock, B. H., et al. (2002). Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nuclear Medicine and Biology, 7(29), 761–770.CrossRef

29.

Fei, X., Zheng, Q. H., Liu, X., Wang, J. Q., Sun, H. B., Mock, B. H., et al. (2003). Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorganic & Medicinal Chemistry Letters, 13(13), 2217–2222.CrossRef

30.

Zheng, Q. H., Fei, X., DeGrado, T. R., Wang, J. Q., Stone, K. L., Martinez, T. D., et al. (2003). Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [¹¹C]methyl ester. Nuclear Medicine and Biology, 7(30), 753–760.CrossRef

31.

Furumoto, S., Takashima, K., Kubota, K., Ido, T., Iwata, R., & Fukuda, H. (2003). Tumor detection using ¹⁸F-labeled matrix metalloproteinase-2 inhibitor. Nuclear Medicine and Biology, 2(30), 119–125.CrossRef

32.

Kopka, K., Breyholz, H. J., Wagner, S., Law, M. P., Riemann, B., Schroer, S., et al. (2004). Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nuclear Medicine and Biology, 2(31), 257–267.CrossRef

33.

Schafers, M., Riemann, B., Kopka, K., Breyholz, H. J., Wagner, S., Schafers, K. P., et al. (2004). Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation, 21(109), 2554–2559.CrossRef

34.

Oltenfreiter, R., Staelens, L., Kersemans, V., Cornelissen, B., Frankenne, F., Foidart, J. M., et al. (2006). Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents. Applied Radiation and Isotopes, 6(64), 677–685.CrossRef

35.

Oltenfreiter, R., Staelens, L., Labied, S., Kersemans, V., Frankenne, F., Noel, A., et al. (2005). Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Cancer Biotherapy & Radiopharmaceuticals, 6(20), 639–647.

36.

Kulasegaram, R., Giersing, B., Page, C. J., Blower, P. J., Williamson, R. A., Peters, B. S., et al. (2001). In vivo evaluation of ¹¹¹In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. European Journal of Nuclear Medicine, 6(28), 756–761.

37.

Seiki, M. (1999). Membrane-type matrix metalloproteinases. APMIS, 1(107), 137–143.CrossRef

38.

Choyke, P. L., Dwyer, A. J., & Knopp, M. V. (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 5(17), 509–520.CrossRef

39.

Weinmann, H. J., Laniado, M., & Mutzel, W. (1984). Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiological Chemistry and Physics and Medical NMR, 2(16), 167–172.

40.

Henderson, E., Sykes, J., Drost, D., Weinmann, H. J., Rutt, B. K., & Lee, T. Y. (2000). Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. Journal of Magnetic Resonance Imaging, 6(12), 991–1003.CrossRef

41.

Ludemann, L., Hamm, B., & Zimmer, C. (2000). Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magnetic Resonance Imaging, 10(18), 1201–1214.CrossRef

42.

Fritz-Hansen, T., Rostrup, E., Larsson, H. B., Sondergaard, L., Ring, P., & Henriksen, O. (1996). Measurement of the arterial concentration of Gd-DTPA using MRI: A step toward quantitative perfusion imaging. Magnetic Resonance in Medicine, 2(36), 225–231.CrossRef

43.

Furman-Haran, E., Margalit, R., Grobgeld, D., & Degani, H. (1996). Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 13(93), 6247–6251.CrossRef

44.

Gore, J. C., Kennan, R. P., & Atlas, S. W. (1996). Magnetic resonance imaging of the brain and spine. Philadelphia: Lippincott-Raven.

45.

Heckl, S., Debus, J., Jenne, J., Pipkorn, R., Waldeck, W., Spring, H., et al. (2002). CNN-Gd(3+) enables cell nucleus molecular imaging of prostate cancer cells: The last 600 nm. Cancer Research, 23(62), 7018–7024.

46.

Wiener, E. C., Konda, S., Shadron, A., Brechbiel, M., & Gansow, O. (1997). Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Investigative Radiology, 12(32), 748–754.CrossRef

47.

Louie, A. Y., Huber, M. M., Ahrens, E. T., Rothbacher, U., Moats, R., Jacobs, R. E., et al. (2000). In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology, 3(18), 321–325.

48.

Frullano, L., Tejerina, B., & Meade, T. J. (2006). Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: A new approach toward prodrug–procontrast complexes. Inorganic Chemistry, 21(45), 8489–8491.CrossRef

49.

Lepage, M., Dow, W. C., Melchior, M., You, Y., Fingleton, B., Quarles, C. C., et al. (2007). Non-invasive detection of matrix metalloproteinase activity using a novel MRI contrast agent with a solubility switch. Molecular Imaging, 6(6), 393–403.PubMed

50.

Marten, K., Bremer, C., Khazaie, K., Sameni, M., Sloane, B., Tung, C. H., & Weissleder, R. (2002). Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology, 2(122), 406–414.CrossRef

51.

Funovics, M. A., Alencar, H., Su, H. S., Khazaie, K., Weissleder, R., & Mahmood, U. (2003). Miniaturized multichannel near infrared endoscope for mouse imaging. Molecular Imaging, 4(2), 350–357.CrossRef

52.

Kawada, S., Suzuki, Y., Hinohara, S., Koide, S., Ono, Y., & Ashikaga, H. (2007). Cancer screening with PET: Advantages and limitations. Rinsho Byori, 7(55), 656–667.

53.

Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., et al. (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical Cancer Research, 8(11), 2785–2808.CrossRef

54.

Albright, C. F., Graciani, N., Han, W., Yue, E., Stein, R., Lai, Z., et al. (2005). Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Molecular Cancer Therapeutics, 5(4), 751–760.CrossRef

55.

Vartak, D. G., & Gemeinhart, R. A. (2007). Matrix metalloproteases: underutilized targets for drug delivery. Journal of Drug Targeting, 1(15), 1–20.CrossRef

56.

Moses, J. E., & Moorhouse, A. D. (2007). The growing applications of click chemistry. Chemical Society Reviews, 8(36), 1249–1262.CrossRef

57.

Cosgrove, D. (2006). Ultrasound contrast agents: an overview. European Journal of Radiology, 3(60), 324–330.CrossRef

58.

Ntziachristos, V., Ripoll, J., Wang, L. V., & Weissleder, R. (2005). Looking and listening to light: the evolution of whole-body photonic imaging. Nature Biotechnology, 3(23), 313–320.CrossRef

Title: Imaging matrix metalloproteinases in cancer
Authors: Randy L. Scherer
J. Oliver McIntyre
Lynn M. Matrisian
Publication date: 01-12-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9152-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma

Imaging of integrin αvβ3 expression

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

Imaging of tumor glucose utilization with positron emission tomography

Tumor detection using folate receptor-targeted imaging agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer